secwatch.observer — SEC 8-K summary
======================================

Issuer:     electroCore, Inc. (ECOR)
CIK:        0001560258
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001493152-26-021493
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

electroCore Q1 revenue $9.6M (+43% YoY); reaffirms ~30% FY2026 growth guidance
------------------------------------------------------------------------------

- Net sales $9.6M, record quarterly revenue, up 43% from $6.7M Q1 2025.
- GAAP net loss $5.3M ($0.59 per share); includes $1.9M leadership transition expenses.
- Adjusted EBITDA net loss improved 24% YoY to $2.3M from $3.1M.
- VA prescription gammaCore revenue grew 26% YoY; Quell Fibromyalgia quarterly sales >$1M.
- Michael Fox appointed COO in April 2026; Truvaga launched in UK in January 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1560258/000149315226021493/0001493152-26-021493-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1560258/000149315226021493/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-021493

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer